Apricus Biosciences (NASDAQ:APRI)

CAPS Rating: 2 out of 5

A pharmaceutical and medical technology company, which conducts research and development both domestically and abroad on proprietary pharmaceutical products.

Results 1 - 13 of 13

Recs

1
Member Avatar zzlangerhans (99.81) Submitted: 2/7/2015 9:15:02 PM : Underperform Start Price: $1.61 APRI Score: +3.16

In January Apricus showed signs of life after a steady six month decline in share price from the 2's. A sharp spike from the lows followed by pullback and consolidation seemed to suggest another move upward would be forthcoming. I flagged that green thumb as a short-termer, since I really don't see any justification for a sustained rebound in the stock. In this case, however, I left points on the table when I closed my green thumb so I'll return to see if I can retrieve them going the other direction.

The only thing that could justify much increase in Apricus's valuation in the short term would be a buyout of the company to acquire control of Vitaros. While this is unlikely, it's not out of the question given recent surprising acquisitions for marketed niche products like Zecuity and Northera. With every notch that Apricus's share price climbs, a buyout becomes less likely and risk/reward tilts in the wrong direction. A much more likely outcome is more distressed financings and a drop in share price below 1.

Recs

0
Member Avatar qualatech (72.09) Submitted: 10/23/2013 2:55:06 PM : Outperform Start Price: $2.03 APRI Score: -41.87

Just received approval for phase testing of ED drug in Europe. Much insider ownership. Little debt. Just registered 1M shares. Management knows something the street doesnt.

Recs

0
Member Avatar thedrew1125 (54.58) Submitted: 2/23/2013 10:58:41 PM : Outperform Start Price: $2.70 APRI Score: -79.04

Gotta give some love to local San Diego companies. That easily-absorbed molecule that they put in their topical treatments will hopefully get some more use.

Recs

0
Member Avatar etra (< 20) Submitted: 11/17/2012 4:33:26 PM : Outperform Start Price: $2.18 APRI Score: -79.63

At present most players of APRI stock buy and then sell almost on a daily basis.The company should convince investment groups that future earnings should enable them to carry the price to $5.00 ..

Recs

0
Member Avatar acts20 (40.51) Submitted: 3/25/2012 5:49:37 PM : Outperform Start Price: $2.96 APRI Score: -96.09

Room to roam

Recs

0
Member Avatar cubanstockpicker (< 20) Submitted: 8/25/2011 6:22:17 PM : Outperform Start Price: $3.97 APRI Score: -142.39

Name reputation alone makes sure founder gets only the best students and the brightest researchers to then turn over the best and brightest products. To then be bought out for more than enough to make us the (you get the idea) profit.

Recs

0
Member Avatar Allstar13913 (99.83) Submitted: 7/30/2011 10:15:59 PM : Underperform Start Price: $3.14 APRI Score: +105.18

Company that is using data-mining to hopefully show a failed drug has potential.

http://www.thestreet.com/_yahoo/story/11169285/1/biotech-data-mining-comes-up-empty.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA

Recs

0
Member Avatar josh28105 (24.06) Submitted: 2/23/2011 5:25:46 AM : Outperform Start Price: $5.09 APRI Score: -129.01

This stock has a lot of good things coming out.

Recs

0
Member Avatar THEMATHISNEAR (< 20) Submitted: 2/17/2011 10:15:30 AM : Underperform Start Price: $4.33 APRI Score: +131.91

Shorting a bunch of rickety-financed biotechs that have run up for no reason. Yes, I expect one to pop, and don't know which one, but I expect that most will fail outright, and the group as a whole will fail to match the S&P.

Recs

0
Member Avatar dmacin (< 20) Submitted: 2/16/2011 9:52:24 PM : Outperform Start Price: $4.20 APRI Score: -120.25

Seems to be moving

Recs

0
Member Avatar dustinmoh6 (< 20) Submitted: 11/23/2010 10:23:07 PM : Outperform Start Price: $3.22 APRI Score: -129.03

Apricus's unique NexACT technology could prove to be very valuable, both from their own drugs and out-licensing to other companies to use. The company has a large arsenal of drugs covering a wide array of health issues. More importantly Apricus's first approved drug, Vitaros, could be a huge winner in the large ED market. It looks as if the company has turned a corner.

Recs

0
Member Avatar dustinm06 (< 20) Submitted: 11/23/2010 9:39:05 AM : Outperform Start Price: $3.49 APRI Score: -131.79

Apricus retains a very innovative core technology called NexACT. This can be blended with already known and effective treatments. NexACT helps these compounds be better absorbed in the body and allows multiple routes of delivery. With an already approved drug, Vitaros, the company has a proven and clinically validated technology it will leverage and monetize.

Recs

1
Member Avatar spikenail (< 20) Submitted: 6/13/2007 12:21:43 PM : Outperform Start Price: $31.20 APRI Score: -143.42

Biotech....pharma tech.....these are the companis that are making all the money in the pharma sector.

Results 1 - 13 of 13

Featured Broker Partners


Advertisement